The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial.
 
Giuseppe Curigliano
Leadership - ESMO; ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Joyce O'Shaughnessy
Honoraria - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Consulting or Advisory Role - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Travel, Accommodations, Expenses - Aptitude Health; Daiichi Sankyo; DAVA Oncology; Lilly; Merck; Novartis; Roche
 
Francois Clement Bidard
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Foresight Diagnostics; Inatherys; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer; Roche; SAGA Diagnostics
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Roche
Research Funding - GE Healthcare (Inst); Menarini Silicon Biosystems (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Personalis (Inst); Pfizer (Inst); Prolynx (Inst); Roche (Inst); SAGA Diagnostics (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - ESR1 & MSI detection techniques (patents) (Inst); Prognosis assessment by a digital pathology assay in early breast cancer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi-Sankyo; Novartis; Pfizer; Roche
 
Sung-Bae Kim
Stock and Other Ownership Interests - Genopeaks
Honoraria - DAEHWA Pharmaceutical; Kalbe Farma; LegoChem Biosciences
Consulting or Advisory Role - AstraZeneca; BeiGene; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Ensol Biosciences; ISU Abxis; Lilly (Inst); OBI Pharma
Research Funding - Genzyme (Inst)
 
Eriko Tokunaga
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan
 
Philippe Aftimos
Honoraria - Gilead Sciences; Roche; Synthon
Consulting or Advisory Role - Amcure; Amgen; Boehringer Ingelheim; Deloitte; G1 Therapeutics; Gilead Sciences; Incyte; Lilly; Macrogenics; Menarini; Novartis; Novartis; Radius Health; Roche; Servier
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; MSD Oncology; Pfizer; Roche Belgium
 
Cristina Saura Manich
Honoraria - AstraZéneca; Daiichi Sankyo/Astra Zeneca; Eisai Europe,Ltd; Exeter Pharmaceuticals; Pfizer; Phillips Health Works; Pierre Fabre; Puma Biotechnology; Roche Pharma AG; Seagen; Solti; Zymeworks
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; F. Hoffmann LaRoche; Gilead Sciences; Lilly; MediTech; Menarini; Menarini; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; SeaGen; Synthon; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Debiopharm Group (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Janssen-Cilag SA (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merck Health KGAA, Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); SERVIER (Inst); Spanish Association Against Cancer Scientific Foundation and Cancer Research UK (Inst); Taiho Pharma USA Inc, (Inst)
Expert Testimony - AX`s consulting SARL; Boehringer Ingelheim; Bristol-Myers Squibb/Sanofi; Genentech; InnoUp; Merck Sharp and Dohme Spain; Novartis; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Gilead Sciences; Lilly; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Puma Biotechnology; Roche; Seagen
 
Lisa Carey
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); NanoString Technologies (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Veracyte (Inst)
(OPTIONAL) Uncompensated Relationships - Reveal Genomics
 
Meena Okera
Consulting or Advisory Role - AstraZeneca; Lilly
Speakers' Bureau - AstraZeneca
Research Funding - multiple (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Éverton Melo
Honoraria - Adium Pharma; AstraZeneca; Janssen; Lilly; Merck; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca; Boehringer Ingelheim; Lilly
 
Flora Zagouri
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD; Novartis; Pfizer Hellas; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
 
Manuel Magallanes
Consulting or Advisory Role - Amgen; Asofarma; AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - Asofarma; AstraZeneca; Lilly; MSD; Pfizer; Roche
Research Funding - Bristol-Myers Squibb; Lilly; Merck; Roche
Travel, Accommodations, Expenses - Janssen; Merck; Novartis
 
Nuri Karadurmus
No Relationships to Disclose
 
Shakeela Bahadur
No Relationships to Disclose
 
Rebecca Speck
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Xuejing Wang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Suzanne Young
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Komal Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Gilead Sciences; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Context Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); RayzeBio (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - AstraZeneca; Daiichi-Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; Viatris; Zuelligpharma
Consulting or Advisory Role - Gilead Sciences; Roche/Genentech; Seagen; West German Study Group (I)
Speakers' Bureau - EPG Communication; Medscape; Springer Healthcare
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)